Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Resistant Ovarian Cancer: A Gynecologic Oncology Group Study


    loading  Checking for direct PDF access through Ovid

Abstract

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.

    loading  Loading Related Articles